Subsea Deoxygenation In A Water Injection Process Plant

US2017253506A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2017253506-A1
Application numberUS-201615058923-A
CountryUS
Kind codeA1
Filing dateMar 2, 2016
Priority dateMar 2, 2016
Publication dateSep 7, 2017
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A water injection process plant includes a catalytic deoxygenation unit located subsea that makes use of a reducing agent sent from topsides in liquid form. The catalyst is preferably a palladium catalyst or its equivalent. The reducing agent is an oxygen scavenger such as but not limited to hydrazine, carbohydrazide, sodium erythorbate, methyl ethyl ketoxime (“MEKO”), hydroquinone, diethylhydroxylamine (“DEHA”), formic acid (methanoic acid). A chemical umbilical can be used to deliver the reducing agent to a mixer located upstream of the deoxygenation unit, where the agent is mixed with seawater containing oxygen.

First claim

Opening claim text (preview).

What is claimed: 1 . A water injection process plant comprising a catalytic deoxygenation unit located subsea and arranged to receive a seawater stream containing oxygen. 2 . A water injection process plant according to claim 1 further comprising a reducing agent, wherein the reducing agent is in liquid form, the catalytic deoxygenation unit being arranged to receive a mixture of the reducing agent and the seawater stream. 3 . A water injection process plant according to claim 2 wherein the reducing agent is selected from the group consisting of hydrazine, carbohydrazide, sodium erythorbate, methyl ethyl ketoxime, hydroquinone, diethylhydroxylamine, and formic acid. 4 . A water injection process plant according to claim 2 further comprising a chemical umbilical arranged to deliver the reducing agent subsea from a topsides source. 5 . A water injection process plant according to claim 2 further comprising a mixer located subsea ahead of the catalytic deoxygenation unit and arranged to receive the seawater stream and the reducing agent. 6 . A water injection process plant according to claim 1 further comprising a filtration system located subsea and arranged to receive a seawater stream. 7 . A water injection process plant according to claim 6 wherein the filtration system includes one or more selectively permeable membranes. 8 . A water injection process plant according to claim 7 wherein the one or more selectively permeable membranes includes a membrane selected from the group consisting of microfiltration, ultrafiltration, nanofiltration, and reverse osmosis. 9 . A water injection process plant according to claim 7 wherein at least one of the selectively permeable membranes is located downstream of the catalytic deoxygenation unit. 10 . A water injection process plant according to claim 1 further comprising a strainer located subsea upstream of the catalytic deoxygenation unit. 11 . A method to deoxygenate a seawater stream subsea, the method comprising the steps of: delivering from topsides to subsea a reducing agent in liquid form; mixing the reducing agent with a seawater stream containing oxygen; and deoxygenating the mixture subsea using a catalytic deoxygenation unit. 12 . A method according to claim 11 wherein the reducing agent is selected from the group consisting of hydrazine, carbohydrazide, sodium erythorbate, methyl ethyl ketoxime, hydroquinone, diethylhydroxylamine, and formic acid. 13 . A method according to claim 11 further comprising the step of filtering the seawater stream using one or more selectively permeable membranes. 14 . A method according to claim 13 wherein the one or more selectively permeable membranes includes a membrane selected from the group consisting of microfiltration, ultrafiltration, nanofiltration, and reverse osmosis. 15 . A method according to claim 13 wherein at least one of the selectively permeable membranes is located downstream of the catalytic deoxygenation unit.

Assignees

Inventors

Classifications

  • C02F1/70Primary

    by reduction {(C02F1/4676 takes precedence)} · CPC title

  • by catalytic oxidation · CPC title

  • Specific process operations in the permeate stream · CPC title

  • Displacing by water · CPC title

  • by ultrafiltration or microfiltration · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2017253506A1 cover?
A water injection process plant includes a catalytic deoxygenation unit located subsea that makes use of a reducing agent sent from topsides in liquid form. The catalyst is preferably a palladium catalyst or its equivalent. The reducing agent is an oxygen scavenger such as but not limited to hydrazine, carbohydrazide, sodium erythorbate, methyl ethyl ketoxime (“MEKO”), hydroquinone, diethylhydr…
Who is the assignee on this patent?
Cameron Solutions Inc
What technology area does this patent fall under?
Primary CPC classification C02F1/70. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Sep 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).